Mirus Corporation
This article was originally published in Start Up
Executive Summary
Gene Therapy. Mirus is exploring technology for transfection reagents and has patents pending on certain protein, lipid and polyamine combinations for gene delivery. These formulations are designed to deliver DNA to cells with minimal toxicitiy. Mirus is already selling off-the-shelf transfection reagents which have been developed for gene transfer into cells in culture.